IMR Press / RCM / Volume 24 / Issue 3 / DOI: 10.31083/j.rcm2403064
Open Access Review
Clinical and Prognostic Value of Exaggerated Blood Pressure Response to Exercise
Show Less
1 Department of Medicine and Surgery, University of Milano-Bicocca, 20126 Milano, Italy
2 Department of Clinical Sciences and Community Health, University of Milano, 20122 Milano, Italy
3 Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy
4 Department of Cardiology, University Hospital “Dr. Dragisa Misovic-Dedinje'', 11000 Belgrade, Serbia
*Correspondence: cesare.cuspidi@unimib.it (Cesare Cuspidi)
Rev. Cardiovasc. Med. 2023, 24(3), 64; https://doi.org/10.31083/j.rcm2403064
Submitted: 13 November 2022 | Revised: 14 December 2022 | Accepted: 30 December 2022 | Published: 22 February 2023
(This article belongs to the Special Issue Cardiac Stress Testing)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

The hypertensive response to exercise testing, defined as exaggerated blood pressure response (EBPR), has been documented to be independently associated with unhealthy conditions, carrying an increased risk of future hypertension, cardiovascular (CV) morbidity and mortality. In treated hypertensives, EBPR is a marker of uncontrolled hypertension, a condition previously undetected by office blood pressure (BP) measurements at rest; EBPR may also detect masked hypertension, a phenotype characterized by normal BP values in the medical environment but elevated home or ambulatory BP monitoring (ABPM). The aim of the present review is to provide a comprehensive and up-dated information on the clinical importance of EBPR targeting the following issues: (I) definition and prevalence; (II) underlying mechanisms; (III) clinical correlates and association with subclinical organ damage; (IV) predictive value; (V) clinical decision making.

Keywords
exaggerated blood pressure response to exercise
hypertension
target organ damage
cardiovascular disease
Figures
Fig. 1.
Share
Back to top